Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa-Reference-Cited by-同舟云学术

Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa

Published:2021-12-22 Issue:6 Volume:6 Page:
ISSN:2379-5042
Container-title:mSphere
language:en
Short-container-title:mSphere

Author:

López-Pérez Mario¹^ORCID,Haro-Moreno Jose M.¹,Molina-Pardines Carmen²,Ventero Maria Paz²^ORCID,Rodríguez Juan Carlos²

Affiliation:

1. Evolutionary Genomics Group, División de Microbiología, Universidad Miguel Hernández, Alicante, Spain

2. Microbiology Department, Alicante University General Hospital, Alicante Institute of Sanitary and Biomedical Research (ISABIAL), Alicante, Spain

Abstract

The growing emergence and spread of carbapenem-resistant pathogens worldwide exacerbate the clinical challenge of treating these infections. Given the importance of carbapenems for the treatment of infections caused by Pseudomonas aeruginosa , this study aimed to investigate the underlying genomic properties of the clinical isolates that exhibited resistance to imipenem and imipenem-relebactam.

Funder

Merck & Co., Inc.

Publisher

American Society for Microbiology

Subject

Molecular Biology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mSphere.00836-21

Reference48 articles.

1. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies

2. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

3. Antibiotic resistance in Pseudomonas aeruginosa – Mechanisms, epidemiology and evolution